Biotech market 2019

Biotech market 2019

While the US cannabis industry is сconquering market share and significantly increasing sales compared to 2017 – biotech stocks are still being treated as a tricky investment decision given that volatility can deform its returns. A highlight of this usually comes along with taboos from the US federal agency of the Food and Drug Administration that may negatively affect the biotech stock prices and put clinical plans on hold.

Fortunately, due to strong earnings reports in 2018 the best biotech stocks can become new investment opportunities going forward. Marketsmith.com has put 2 leading biotech stocks on a list of the 150 fastest growing companies for 2018 – Supernus Pharmaceuticals and Ligand Pharmaceuticals. Our bonus stock is Immunomedics – a new promising biotech company with incredible growth in 2018 alone.

SUPNis ranked 13 among top fast growing stocks with EPS growth of 138% in the last five years – a massive increase thus far. Although Supernus has gained rep as highly innovative company, the market cap is still lower than other multimillion biotech companies, such as Celgene (CELG), Biogen (BIIB), Amgen (AMGN) and Gilead Sciences (GILD). Regardless of strong rivals, SUPN positions itself as a top biotech company in terms of performance metrics. Make sure you do due-diligence before jumping in on the stock – technicals and fundamentals are really important for long-term investment evaluation.

Supernus has revealed outstanding QEs sales over the past several years which have been generated mainly due to unique drugs for CNS disorders like epilepsy medicaments Oxtellar XR and Trokendi XR. In addition, Trokendi XR is authorized to cure migraines, same as rival drug from Allegran (AGN).

The next biotech stock off the list of possible investments for 2019 is Ligand Pharmaceuticals (LGND) – a unique company with no single drug in the market. Being ranked 139 out of 150, Ligand focus on acquiring technologies aimed for the drug development process. The company then issue a license to big pharmaceutical corps like Merck (MRK) and Pfizer (PFE) to use these technological platforms. Ligand have been showing five QEs in a row with double-digit growth and over triple-digit sales as per latest QE in June 2018. Further to this, LGND runs a IBD Composite Rating with a score of 99 which makes it perform among the top 1% stocks as regards KPIs. It outperforms large biotech stock like Vertex Pharmaceuticals (VRTX) with 97 in IBD.

Our next candidate for the best biotech stock/possible investment in 2019 isImmunomedics (IMMU) – a pharmaceutical company that is exploring cancer treatment by its antibody-drug conjugate drugs. This is a leader in the industry!The IMMU stocks have spiked in price in 2018 (to all time-high at $27.33 in September) amid the launch of the company’s lead drug IMMU-132–the one with a PDUFA deadline in January 2019. Numbers speak for themselves: IMMU climbed 51% in the current year and reached over 103% growth on year-to-year basis. Investors are stepping in and buying this biotech stock while on bullish surge. Meanwhile, the market cap has yet hit the $3.74bn mark.

Sources: https://seekingalpha.com/ https://marketsmith.investors.com/

Add a Comment

Your email address will not be published. Required fields are marked *